Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: EC:4.6.1.2 (guanylate cyclase)
 8,497 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

We have shown previously that oestradiol elevates the cGMP content od isolated uterine horns incubated for 2 h with the hormone. Cycloheximide (30 micrograms/ml) or actinomycin D (100 micrograms/ml), at concentrations which markedly inhibit protein and RNA synthesis, blocked the oestrogen-induced increase in cGMP. These agents do not inhibit the rise in uterine cGMP content provoked by sodium nitroprusside, thus arguing against a direct toxic effect on the enzyme guanylate cyclase. alpha-Amanitin, even at very high concentrations (80 micrograms/ml), interfered much less efficiently with total RNA and protein synthesis and also failed to prevent the oestrogen-induced increase in cGMP content. Taken together, these observations indicate that oestrogen action on uterine cGMP concentration in vitro depends on an RNA and/or a protein biosynthetic event that takes places in the uterus. This therefore confirms and extends analogous observations made previously under conditions in vivo.
 ...
PMID:Oestrogen-induced increase in uterine cGMP content in vitro: effects of inhibitors of protein and RNA synthesis. 617 45